YD Bio Limited showcased its latest advancements in DNA methylation-based cancer detection and ophthalmologic innovations at the 9th Healthcare Expo Taiwan, held from December 4-7, 2025, at TaipeiNEX 1. Presenting at Booth No. 4F, M1004, the company highlighted its early cancer detection technologies, precision diagnostics, and stem cell therapy platforms. YD Bio engaged with over 1,500 visitors and conducted 541 on-site surveys, connecting with key industry stakeholders and international distributors. The event marked a significant step in YD Bio's global commercialization strategy, with strong interest from partners in China, Hong Kong, Indonesia, and Dubai to expand the reach of its OkaiDx™ and other diagnostic products.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. YD Bio Limited published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9599259) on December 09, 2025, and is solely responsible for the information contained therein.